Navigation Links
Anthera Announces Completion of Safety Review by DSMB for VISTA-16
Date:12/14/2011

(atorvastatin calcium) to reduce secondary Major Adverse Cardiovascular Events in patients who have recently experienced an Acute Coronary Syndrome. In February 2010, Anthera received a SPA from the U.S. FDA for the VISTA-16 Phase 3 study for the use of varespladib in treating high-risk ACS patients.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has three late stage clinical products: varespladib methyl (A-002), A-001 and blisibimod (A-623). Varespladib methyl (A-002) and A-001 are designed to inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA2). Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF) which have been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus) and rheumatoid arthritis.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including A
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer
2. Anthera Pharmaceuticals Reports 2011 Third Quarter Financial Results and Operational Update
3. Anthera Announces Last Patient Enrolled in PEARL-SC Study
4. Anthera Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application Covering A-002 Plus Statin Compositions
5. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
6. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
7. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8. Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
9. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
10. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
11. Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... WORTH, Texas , December 18, 2014 /PRNewswire/ ... a networked software application/module that is used to ... related images. RIS comprises a patient tracking and ... system. The integration of RIS with HIS and ... used for patient registration and patient scheduling, patient ...
(Date:12/19/2014)... REDWOOD CITY, Calif., Dec. 18, 2014 ... on the development of medical diagnostics based on ... of gas flow, today announced financial results for ... 30, 2014. "Following the completion of ... well positioned to maximize the recently initiated CoSense® ...
(Date:12/19/2014)... , Dec. 19, 2014  Eli Lilly and ... Paris: FR0011184241 – ADOC) today announced a worldwide licensing ... BioChaperone Lispro, for treatment in people with type 1 ... proprietary BioChaperone® technology and is currently in Phase Ib ... Lispro with the goal of optimizing glucose levels during ...
Breaking Medicine Technology:The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... , MORRISTOWN, N.J. , May 24 Watson ... subsidiary, Watson Laboratories, Inc., has received approval from the United States ... for Valacyclovir Hydrochloride tablets, USP, in the 500 and 1000 mg ... to begin shipping the product shortly.   , ...
... Genzyme Corp. has signed a consent decree agreeing to correct manufacturing quality violations at ... government $175 million in unlawful profits from the sale of products that ... , , ... , , ...
Cached Medicine Technology:Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 2Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 3Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 2Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 3
(Date:12/21/2014)... Recently, one of the best prom ... Shop has introduced its new collection of 2015 ... discounts on all its prom dresses & other fashionable ... on providing top quality dress products and great customer ... as one of the best prom dresses online shops ...
(Date:12/21/2014)... 21, 2014 Over the past 39 ... in hundreds of emergency departments across the nation, from ... have been translated into an innovative suite of tools, ... deficiencies and enhance the patient experience. , NES ... staffing and management services for hospitals, announced the development ...
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation hosted ... Whittier offices. The Hope for the Holidays Toy Drive is ... their families during the holiday season. This year, the toy ... between both offices. This event continues to be successful year ... team, store managers and assistant managers came out and not ...
(Date:12/20/2014)... Weddingshe.com has recently announced its new ... promotion of special occasion dresses for the coming new ... special occasion dresses for global women. Now, all the ... up to 80% off. Among the new items, the ... 16 Dress) is very popular. What’s more, Weddingshe.com also ...
(Date:12/20/2014)... 20, 2014 (HealthDay News) -- The holidays can be ... contend with fresh trees, scented candles and other allergy ... the decorations that have been packed away in dank ... allergy and asthma patients," Dr. Rachna Shah, an affiliate ... Medicine, said in Loyola news release. Shah, who ...
Breaking Medicine News(10 mins):Health News:New Prom Dresses From One Of The Best Prom Dresses Online Shops, LunaDress Prom Shop 2Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:Holiday Trimmings Can Trigger Allergies 2
... The Reeve Foundation debuts new national ad campaign giving ... HILLS, N.J., Nov. 3 The Christopher & Dana ... advertising,campaign. The campaign presents an edgier side of the ... life is like through the eyes of,someone living with ...
... critical need to review current treatment strategies for the ... to a series of international papers in the November ... with severe disability, unmet treatment need and little clinical ... Professor David W Dodick from the Mayo Clinic College ...
... 3 Pregis Corporation, a leading,international manufacturer, ... specialty packaging solutions, will conduct an investor,conference ... results on Friday,November 14, 2008 at 10:00 ... 617-614-4909; Participant Passcode: 68623125. A replay of,the ...
... crucial element in hip,fracture recovery, ROSEMONT, Ill., ... fracture are referred to their primary care physicians ... published in the,November 2008 issue of The Journal ... an osteoporosis management program initiated by an,orthopaedic surgeon ...
... LifeNet Health,a leading allograft bio-implant company, ... United States Food and Drug Administration (FDA) ... technology., LifeNet Health received clearance for ... donor cells from cardiovascular tissues,while retaining the ...
... (Nasdaq: BMRN ) announced today the initiation ... with the lysosomal storage disease,Mucopolysaccharidosis Type IVA (MPS ... augment available data on the disease by measuring ... patients.,BioMarin expects to follow the MorCAP program with ...
Cached Medicine News:Health News:Christopher & Dana Reeve Foundation Launches First-Ever National Advertising Campaign 2Health News:Urgent need for research into the best treatment for medication overuse headaches 2Health News:Urgent need for research into the best treatment for medication overuse headaches 3Health News:Urgent need for research into the best treatment for medication overuse headaches 4Health News:Treating Osteoporosis After Hip Fracture 2Health News:Treating Osteoporosis After Hip Fracture 3Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 2Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 3Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 4
BD Vacutainer® Specialty Tubes - Trace Element - Plastic...
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Medicine Products: